Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Paediatric neurodegenerative diseases are frequently caused by inborn errors in glycosphingolipid (GSL) catabolism and are collectively termed the glycosphingolipidoses. GSL catabolism occurs in the lysosome and a defect in an enzyme involved in GSL degradation leads to the lysosomal storage of its...
Main Authors: | Jeyakumar, M, Butters, T, Dwek, R, Platt, F |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
by: Butters, T, et al.
Published: (2003) -
Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
by: Butters, T, et al.
Published: (2000) -
New developments in treating glycosphingolipid storage diseases.
by: Platt, F, et al.
Published: (2005) -
Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
by: Platt, F, et al.
Published: (2000) -
Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
by: Priestman, D, et al.
Published: (2008)